Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divozilimab in Neuromyelitis Optica Spectrum Disorders
NCT05730699Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Divozilimab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by BIOCAD. Primary endpoint: Adjudicated Annualized Relapse Rate at 24 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
Divozilimab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05730699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730699.